Viamet Pharmaceuticals Holdings, LLC

Viamet Pharmaceuticals Holdings, LLC, a biopharmaceutical company, focuses on the discovery, development, and commercialization of novel antifungal agents based on its proprietary metalloenzyme medicinal chemistry platform. Its lead product candidate, VT-1161, is an oral agent that is in Phase IIa clinical trial development for the treatment of moderate to severe acute vulvovaginal candidiasis; and moderate to severe interdigital tinea pedis, a dermatologic infection. The company is also developing VT-1129, an oral agent in preclinical development for the treatment of cryptococcal meningitis, an invasive fungal infection of the lining of the brain and spinal cord; and VT-1598 and related analogues, which are in preclinical development to identify the optimal candidate to advance in development as an oral and intravenous therapy for the treatment of invasive fungal infections. Viamet Pharmaceuticals Holdings, LLC is based in Durham, North Carolina.